<i>Did you smoke?</i> Addressing stigma in lung cancer

McLaughlin‐Barrett, Sara; Brunelli, Vanessa

doi:10.1111/resp.14161

Cited by 5 publications

(9 citation statements)

References 3 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Indeed, the participants from both samples considered the person's behavior most acceptable when they had quit smoking, judging the behavior of the person thinking about quitting smoking comparatively less acceptable, and the behavior of the person who continued smoking to have a very low acceptability. This certainly illustrates with quantitative data the current vivid stigmatization around smoking (McLaughlin-Barrett & Brunelli, 2021;Scharnetzki & Schiller, 2021). On the same theme, the smoking habits factor, that is, smoking 1−2 or 20 cigarettes daily, showed higher acceptability of the character's behavior for the lowest consumption, with a medium effect size.…”

Section: Discussionsupporting

confidence: 60%

“…As a consequence, when patients reveal their diagnosis to their social network, a frequent reply is "Did you smoke?" or "I didn't know you smoke," impulsive reactions that plague people living with lung cancer (McLaughlin-Barrett & Brunelli, 2021). This vivid current stigmatization around smoking may be a negative effect of antitobacco campaigns run in the past decades.…”

mentioning

confidence: 99%

“…The stigmatization of lung cancer most likely results from the stigmatization around tobacco smoking (McLaughlin-Barrett & Brunelli, 2021; Rose et al, 2022; Scharnetzki & Schiller, 2021). As a consequence, when patients reveal their diagnosis to their social network, a frequent reply is “Did you smoke?” or “I didn’t know you smoke,” impulsive reactions that plague people living with lung cancer (McLaughlin-Barrett & Brunelli, 2021). This vivid current stigmatization around smoking may be a negative effect of antitobacco campaigns run in the past decades.…”

mentioning

confidence: 99%

See 2 more Smart Citations

Is smoking acceptable for lung cancer patient? Factors influencing the stigmatization.

Auriol,

Cantisano,

Raynal

2023

Stigma and Health

View full text Add to dashboard Cite

Lung cancer is a disease with strong stigma due to stigmatization around smoking. Reducing stigma could be favorable for patients but requires to identify factors influencing this stigmatization. This study aimed to analyze people’s acceptability judgments regarding smokers’ behaviors concomitant to a lung cancer diagnosis. This study used a quantitative method to identify variables involved in one’s judgment, based on a comprehensive combination of scenarios rated by participants on an acceptability scale. Scenarios were built using factors putatively influencing participants’ judgment of a woman character diagnosed with lung cancer, including smoking habits, type of diagnosis/prognosis, and postdiagnosis smoking behavior. Two different samples were studied: 132 community individuals and 126 health professionals. Data were analyzed using within-subject factorial analysis of variance and t tests. In both samples, the postdiagnosis behavior had large effect sizes, with smoking cessation being more acceptable than other smoking behaviors. Other factors, including diagnosis and smoking habits, had significant influences on participants’ judgments, with small to medium effect sizes. Diagnosis had a stronger effect size when interacting with postdiagnosis behavior, as the acceptability by health professionals of continuing smoking was almost doubled when the character had advanced rather early stage cancer. The lesser the smoking behavior, the better the acceptability. However, advanced cancer stage attenuated the poor acceptability of smoking in health professionals, and, to a lower extent, in community individuals, as these participants’ attitudes were more permissive when the patient had advanced cancer. This could substantiate the higher distress recently reported in early stage lung cancer patients. This study illustrates with quantitative data the stigmatization toward lung cancer patients when smoking subsists. In terms of implications for practice, these findings could allow to identify, as early as the time of diagnosis, the persons the most at risk of being stigmatized, in order to reduce the impact of stigma. Indeed, according to this study, the profile of the most stigmatized individuals would be those with early stage lung cancer who smoked heavily before diagnosis and who continue smoking after diagnosis.

show abstract

Section: Discussionsupporting

confidence: 60%

mentioning

confidence: 99%

mentioning

confidence: 99%

See 1 more Smart Citation

Is smoking acceptable for lung cancer patient? Factors influencing the stigmatization.

Auriol,

Cantisano,

Raynal

2023

Stigma and Health

View full text Add to dashboard Cite

show abstract

“…In over 10,000 patients representing various treatments and all stages of disease, survival improved with smoking cessation in both NSCLC (non‐small cell lung cancer) (Figure 1) and SCLC (small cell lung cancer). Stigma in lung cancer, a major cause of distress, derives much of its power from links to smoking 36 . Without full engagement in smoking cessation as a major therapeutic strategy, the lung cancer community may deny patients the best possible outcomes 37 …”

Section: Lung Cancer Updatementioning

confidence: 99%

“…Stigma in lung cancer, a major cause of distress, derives much of its power from links to smoking. 36 Without full engagement in smoking cessation as a major therapeutic strategy, the lung cancer community may deny patients the best possible outcomes. 37…”

Section: Smoking Cessation In Lung Cancermentioning

confidence: 99%

Contemporary Concise Review 2021: Pulmonary nodules from detection to intervention

Leong

2022

Respirology

View full text Add to dashboard Cite

The US Preventive Task Force (USPSTF) has updated screening criteria by expanding age range and reducing smoking history required for eligibility; the International Lung Screen Trial (ILST) data have shown that PLCOM2012 performs better for eligibility than USPSTF criteria.• Screening adherence is low (4%-6% of potential eligible candidates in the United States) and depends upon multiple system and patient/candidate-related factors.• Smoking cessation in lung cancer improves survival (past prospective trial data, updated meta-analysis data); smoking cessation is an essential component of lung cancer screening. • Circulating biomarkers are emerging to optimize screening and early diagnosis.• COVID-19 continues to affect lung cancer treatment and screening through delays and disruptions; specific operational challenges need to be met. • Over 70% of suspected malignant lesions develop in the periphery of the lungs.Bronchoscopic navigational techniques have been steadily improving to allow greater accuracy with target lesion approximation and therefore diagnostic yield. • Fibre-based imaging techniques provide real-time microscopic tumour visualization, with potential diagnostic benefits. • With significant advances in peripheral lung cancer localization, bronchoscopically delivered ablative therapies are an emerging field in limited stage primary and oligometastatic disease. • In advanced stage lung cancer, small-volume samples acquired through bronchoscopic techniques yield material of sufficient quantity and quality to support clinically relevant biomarker assessment.

show abstract

Understanding persistent breathlessness: impact on patients and optimal approaches to symptomatic reduction – an overview

Kochovska

Brunelli

Currow

2023

Expert Review of Respiratory Medicine

View full text Add to dashboard Cite

Did you smoke? Addressing stigma in lung cancer

Cited by 5 publications

References 3 publications

Is smoking acceptable for lung cancer patient? Factors influencing the stigmatization.

Is smoking acceptable for lung cancer patient? Factors influencing the stigmatization.

Contemporary Concise Review 2021: Pulmonary nodules from detection to intervention

Understanding persistent breathlessness: impact on patients and optimal approaches to symptomatic reduction – an overview

Contact Info

Product

Resources

About